Form 4: Viracta Therapeutics CFO Daniel Chevallard Reports Stock Transactions

Daniel Chevallard, CFO and COO of Viracta Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Summary

• Daniel Chevallard, CFO and COO of Viracta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 25, 2024, Chevallard acquired 6,889 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.00.
• On February 27, 2024, Chevallard disposed of 3,405 shares of common stock at a weighted average price of $0.7322 to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Chevallard beneficially owns 102,306 shares of Viracta Therapeutics common stock and 34,444 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation and tax obligations.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be an indicator of management's confidence in the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small number of shares involved.
• Employees holding RSUs may be affected by the vesting schedule and associated tax obligations.

Key Dates

Keywords

Form 4, Viracta Therapeutics, Daniel Chevallard, Stock Transactions, Beneficial Ownership, RSU, VIRX